Penn Medicine Provider
Hematology
Stefan K. Barta, MD, MS, MRCPCUK
5.0
(589)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Director, T-Cell Lymphoma Program
  • Executive Officer, AIDS Malignancy Consortium
  • Associate Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Johann Wolfgang Goethe University
  • Residency: Whipps Cross University Hospital
  • Residency: Burnley General Teaching Hospital
  • Residency: The Whittington Hospital
  • Residency: The St. Bartholomew's and The Royal London
  • Residency: Mount Sinai Morningside
  • Fellowship: The St. Bartholomew's and The Royal London
  • Fellowship: Montefiore Medical Center

What my patients think about me

Average Rating
5.0

589 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
they're the best
May 2025
5.0
5.0
professional and knowledgeable
May 2025
5.0
5.0
all was great
April 2025
5.0
5.0
very personable

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Barta is a Penn Medicine physician.

Qualifications and experience

My research

Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK. Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience , Clin Lymphoma Myeloma Leuk: 2025


Thomas CJ, Porter D, Van Deerlin VM, Bhattacharyya S, Carvajal V, Kim J, Priore S, Yang G, Gerson JN, Barta SK. Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia , Leuk Lymphoma: 2025


Danilov AV, Sauter C, Phillips T, Coombs CC, Ip A, Wang Y, Rhodes J, Leslie L, Barrientos J, Saeed H, Strati P, Barta SK, Shadman M. Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference , Clin Lymphoma Myeloma Leuk: 2025


Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy , Transplant Cell Ther: 2025


Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective Cohort Study of Novel Oral Agents Lenalidomide and Duvelisib For Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome , J Am Acad Dermatol: 2024


Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ. Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP , Haematologica: 2024


Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier AC. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation , Blood Adv, 8: 2024,5458-5466


Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF. Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression , Cancer Res Commun, 4: 2024,2947-2954


Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study , Lancet Oncol: 2024


Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmán A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla N. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study , Blood Cancer J, 14: 2024,182